報價延遲最少15分鐘:2026/04/15 09:42 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.13/0.83
|
|
企業價值
3.23B
|
| 資產負債 |
|
每股賬面淨值
1.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
376.07M
|
|
每股收益
0.40
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. |
